SK74697A3 - Tachykinin antagonists, preparation method thereof and pharmaceutical composition containing the same - Google Patents
Tachykinin antagonists, preparation method thereof and pharmaceutical composition containing the same Download PDFInfo
- Publication number
- SK74697A3 SK74697A3 SK746-97A SK74697A SK74697A3 SK 74697 A3 SK74697 A3 SK 74697A3 SK 74697 A SK74697 A SK 74697A SK 74697 A3 SK74697 A3 SK 74697A3
- Authority
- SK
- Slovakia
- Prior art keywords
- phenyl
- hydrogen
- formula
- compound
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
| PCT/EP1995/004910 WO1996018643A1 (fr) | 1994-12-13 | 1995-12-12 | Antagonistes de la tachykinine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK74697A3 true SK74697A3 (en) | 1997-11-05 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK746-97A SK74697A3 (en) | 1994-12-13 | 1995-12-12 | Tachykinin antagonists, preparation method thereof and pharmaceutical composition containing the same |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (fr) |
| JP (1) | JPH10511935A (fr) |
| AR (1) | AR001332A1 (fr) |
| AU (1) | AU4343796A (fr) |
| BR (1) | BR9509997A (fr) |
| CA (1) | CA2204130A1 (fr) |
| CO (1) | CO4700289A1 (fr) |
| CZ (1) | CZ179097A3 (fr) |
| FI (1) | FI971685A (fr) |
| HU (1) | HUT77002A (fr) |
| IL (1) | IL116323A0 (fr) |
| NO (1) | NO972526D0 (fr) |
| PE (1) | PE38997A1 (fr) |
| PL (1) | PL320217A1 (fr) |
| SK (1) | SK74697A3 (fr) |
| TR (1) | TR199501568A2 (fr) |
| WO (1) | WO1996018643A1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| CA2266773A1 (fr) * | 1996-10-07 | 1998-04-16 | Merck Sharp & Dohme Limited | Utilisation de l'antagoniste du recepteur nk-1 utilise comme antidepresseur et/ou agent anxiolytique |
| KR100699404B1 (ko) | 1999-02-18 | 2007-03-23 | 가켄 세야쿠 가부시키가이샤 | 성장 호르몬 분비촉진제로서의 신규 아미드 유도체 |
| CN101119969B (zh) | 2004-07-15 | 2014-04-09 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
| WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
| JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
| EP1940842B1 (fr) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (fr) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
| EP2145884B1 (fr) | 2007-04-02 | 2014-08-06 | Msd K.K. | Dérivé d'indoledione |
| WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
| WO2009111354A2 (fr) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Inhibiteurs de la tyrosine kinase |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
| ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
| ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
| ES2528404T3 (es) | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
| WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
| EP2584903B1 (fr) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
| WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
| EP3587574B1 (fr) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP2632472B1 (fr) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina) |
| WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
| WO2012145471A1 (fr) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3919620A1 (fr) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
| US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| PL2925888T3 (pl) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Kompozycje i sposoby do stosowania w leczeniu nowotworów |
| CA2895504A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituees en tant qu'inhibiteurs de hdm2 |
| WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/fr not_active Application Discontinuation
- 1995-12-12 CA CA002204130A patent/CA2204130A1/fr not_active Abandoned
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 EP EP95942131A patent/EP0797583A1/fr not_active Withdrawn
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
-
1997
- 1997-04-18 FI FI971685A patent/FI971685A/fi not_active Application Discontinuation
- 1997-06-03 NO NO972526A patent/NO972526D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT77002A (hu) | 1998-03-02 |
| NO972526L (no) | 1997-06-03 |
| WO1996018643A1 (fr) | 1996-06-20 |
| PL320217A1 (en) | 1997-09-15 |
| PE38997A1 (es) | 1997-10-02 |
| AR001332A1 (es) | 1997-10-22 |
| BR9509997A (pt) | 1997-12-30 |
| TR199501568A2 (tr) | 1996-07-21 |
| IL116323A0 (en) | 1996-03-31 |
| CZ179097A3 (en) | 1997-10-15 |
| AU4343796A (en) | 1996-07-03 |
| CO4700289A1 (es) | 1998-12-29 |
| FI971685A0 (fi) | 1997-04-18 |
| FI971685A (fi) | 1997-08-13 |
| NO972526D0 (no) | 1997-06-03 |
| EP0797583A1 (fr) | 1997-10-01 |
| CA2204130A1 (fr) | 1996-06-20 |
| JPH10511935A (ja) | 1998-11-17 |
| MX9703957A (es) | 1997-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK74697A3 (en) | Tachykinin antagonists, preparation method thereof and pharmaceutical composition containing the same | |
| AU742941B2 (en) | Sustained release tablet formulation to treat parkinson disease | |
| JP6999639B2 (ja) | 置換ジアザヘテロ－二環式化合物およびそれらの使用 | |
| TW201041866A (en) | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | |
| JP2018536693A (ja) | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 | |
| JP2018538296A (ja) | 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 | |
| SK3898A3 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| JP2003505435A (ja) | メラノコルチン−４受容体ゴニストとしての置換ピペリジン | |
| JPH07215863A (ja) | 非ペプチドタキキニン受容体拮抗物質 | |
| JP3817256B2 (ja) | タキキニンアンタゴニスト | |
| EA029097B1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| CN103237795B (zh) | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 | |
| JP3068458B2 (ja) | クロモン誘導体 | |
| US20050245532A1 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | |
| EP1120416A1 (fr) | Pyrido[2.3-b][1,4]benzodiazépinones en tant que ligand de récepteur M2 pour le traitement de troubles neurologiques | |
| US20050245533A1 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | |
| EP0747055A2 (fr) | Utilisation d'antagonistes du récepteur de tachykinine pour le traitement du rhume et de la rhinite allergique | |
| HU205920B (en) | Process for producing 2-phenoxy-methyl/-3-/alkanoyl-, carboxy-, carbalkoxy- or carboxamido- -acetyl/-1,3-thiazolidine derivatives and pharmaceutical compositions containing them | |
| JP2004508272A (ja) | アセチルコリンエンハンサー | |
| JPS6230762A (ja) | 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体 | |
| CZ173094A3 (en) | The use of n-(pyridinyl)-1h-indol-1-amines for the preparation of a medicament for treating compulsions | |
| MXPA01001461A (es) | Metabolitos de difenhidramina no sedantes. | |
| JP2002515912A (ja) | 目に関連する病気の処置のためのソマトスタチン作動因子及び拮抗因子の利用 | |
| JP4355144B2 (ja) | 新規含窒素環状化合物 | |
| MXPA97003957A (en) | Antagonists of taquicin |